The 10-second takeawayFor the quarter ended June 30 (Q2), Accretive Health met expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly and GAAP earnings per share dropped to a loss.

Margins contracted across the board.

Revenue detailsAccretive Health booked revenue of $236.7 million. The eight analysts polled by S&P Capital IQ expected to see revenue of $235.3 million on the same basis. GAAP reported sales were 29% higher than the prior-year quarter's $183.6 million.

Looking aheadNext quarter's average estimate for revenue is $236.8 million. On the bottom line, the average EPS estimate is $0.11.

Next year's average estimate for revenue is $977.3 million. The average EPS estimate is $0.41.

Investor sentimentThe stock has a two-star rating (out of five) at Motley Fool CAPS, with 36 members rating the stock outperform and five members rating it underperform. Among seven CAPS All-Star picks (recommendations by the highest-ranked CAPS members), six give Accretive Health a green thumbs-up, and one gives it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Accretive Health is outperform, with an average price target of $13.67.

Seth Jaysonhad no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.